Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Analysis of Differences in Living Donor and Recipient Pairs Estimated GFR at Six Months Over Time.
D. Keith.
Medicine, Division of Nephrology, Sacred Heart Hospital, Pensacola, FL
Previous studies of the United States Kidney Transplant Database revealed that the median estimated GFR (eGFR) has improved over the last decade for living donor…
2017 American Transplant Congress
Experience with Obinutuzumab (Type II Anti-CD20) in Kidney Transplant Patients with Donor Specific Antibody (DSA+) Antibody Mediated Rejection.
J. Choi, A. Vo, E. Huang, S. Louie, A. Kang, A. Peng, R. Najjar, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Introduciton:Rituximab is a type I chimeric IgG1 anti-CD20 antibody that has revolutionized the management and treatment of B-cell malignancies, and numerous autoimmune diseases. In addition,…
2017 American Transplant Congress
Five-Year Outcomes After Transplantation of Kidneys from Deceased Donors with Acute Kidney Injury.
J. Latona,¹ A. Shah,^1,2 A. Frank,^1,2 W. Maley,^1,2 C. Doria,^1,2 C. Ramirez.^1,2
¹Division of Transplant Surgery, Thomas Jefferson University, Philadelphia, PA; ²Kidney Transplant Program, Lankenau Medical Center, Wynnewood, PA
Background: Kidneys from deceased donors with acute kidney injury (AKI) are often discarded due to a perceived higher risk of poor graft function. Kidney Donor…
2017 American Transplant Congress
Impact of Type of Recipient Diabetes on 1 and 3-Year Kidney Allograft and Patient Outcomes.
S. Kim, F. Wu, D. Cibrik, Y. Li, A. Naik.
University of Michigan, Ann Arbor
The pathophysiology of type 1 (T1DM) and type 2 (T2DM) diabetes is different and has been conjectured to impact transplantation outcomes differently over time especially…
2017 American Transplant Congress
Specific Gene Expression Signature of Complement-Activating Donor Specific Anti-HLA Antibody-Mediated Rejection in Kidney Allografts.
C. Lefaucheur,¹ D. Viglietti,¹ L. Hidalgo,² O. Aubert,¹ A. Zeevi,³ P. Halloran,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Alberta, Edmonton, Canada; ³University of Pittsburgh Medical Center, Pittsburgh
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft survival. However, their specific effects on rejection pathogenesis have not been identified. We investigated…
2017 American Transplant Congress
Gut Microbial Metabolite Improves Function and Prolongs Kidney Allograft Survival in Mice.
H. Wu,^1,2 T. Kwan,¹ Y. Loh,¹ X. Chen,¹ L. Macia,^2,3 S. Alexander,^2,4 S. Chadban.^1,2
¹Kidney Node Laboratory, The Charles Perkins Centre and Renal Medicine, Sydney Medical School and Royal Prince Alfred Hospital, Sydney, Australia; ²University of Sydney, Sydney, Australia; ³Nutritional Immunometabolism Lab, The Charles Perkins Centre, Sydney Medical School, Sydney, Australia; ⁴Nephrology Department, The Children Hospital at Westmead, Sydney, Australia
To determine the impact of dietary administration of the gut microbial metabolite sodium acetate (SA) on kidney rejection and survival in a fully MHC-mismatched murine…
2017 American Transplant Congress
Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients.
D. Taber, M. Gebregziabher, L. Egede, P. Baliga.
MUSC, Charleston, SC
Disparities research has traditionally focused on patient-level variables to ascertain predominant risk factors driving differences in outcomes for African-American (AA) kidney transplant (KTX) recipients. The…
2017 American Transplant Congress
IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.
H. Xu, T. Brennan, A. Kirk.
Department of Surgery, Duke University School of Medicine, Durham, NC
Transplant patients treated with belatacept without depletional induction show high rates of costimulation blockade resistant rejection (CoBRR); this has been associated with CD57+ T cells.…
2017 American Transplant Congress
Early Antibody-Mediated Rejection C4d Status Remains a Marker of Prognosis in HLA-Incompatible Kidney Transplantation.
J. Malheiro,¹ S. Santos,¹ S. Tafulo,² L. Dias,¹ L. Martins,¹ J. Ramon,¹ A. Castro-Henriques.¹
¹CHP, Porto, Portugal; ²IPST, Porto, Portugal
Banff criteria for the diagnosis of antibody-mediated rejection (AMR) in kidney transplantation (KT) was recently updated to include the entity of C4d negative AMR, if…
2017 American Transplant Congress
Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.
A. Vo,¹ S. Williamson,¹ K. Myers,¹ E. Huang,¹ J. Choi,¹ X. Zhang,² A. Peng,¹ R. Najjar,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA
Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…